India sees sizable improvement in finished dosage reputation and growth ahead of CPhI India 2021

by CPhI India Contributor

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or
Contributors are fully responsible for assuring they own any required copyright for any content they submit to This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   212    Comments 0

CPhI & P-MEC India delivers hybrid event as country improves across all key performance metrics in CPhI global survey

CPhI & P-MEC India – organised by Informa Markets – is set to welcome attendees and exhibitors from around the world, both online and in-person, as new CPhI analysis points to sustained pharma growth in India, with an improving outlook for finished dosage, API and biologics.

The India-specific findings of the CPhI Annual Report survey[1], conducted among 350 executives, point to a significant jump in the country’s global reputation with India widely perceived to be benefiting from post pandemic macro-economic and supply chain changes.

With these positive results and growth forecast as the event’s backdrop, the 14th Annual CPhI & P-MEC India will run in a hybrid form, with an online conference and networking from 15-30 November alongside an in-person event in New Delhi on 24-26 November. India also recently opened to international visitors by issuing visas and easing inbound travel restrictions, which is likely to positively impact the return of onsite international networking.

“There is a tremendous need for new manufacturing partners and as shown in the report – Indian manufacturers in particular are in high demand. By delivering a hybrid event and offering a platform where international and national buyers and suppliers can profile themselves, we are facilitating greater opportunity for future partnerships,” commented Silvia Forroova, Brand Director at Informa.

India’s single biggest metric improvement in the CPhI data was in the perceived quality of ‘finished dose manufacturing’, where the country surged 13% in year, adding to the 4% rise in saw in 2020, while it also jointly topped the prestigious ‘growth potential’ category with the United States for the first time.

In fact, across all Indian manufacturing there has been tremendous growth in the last year, Sriram Shrinivasan, Consulting CHS Leader at Ernst & Young India commented: “Indian contract manufacturing exported goods worth around 10 billion dollars in 2020, and is expected to reach 27-28 billion dollars by 2026, which equates to a fantastic 18-20% CAGR during this period. Also, there is a lot more focus on outsourcing, resourcing and manufacturing into India. This trend is fuelled by India’s reputation for quality, infrastructure , growing innovation ecosystem and its skilled workforce –  one of the largest pool of STEM graduates globally”.

India also saw its reputation for API manufacturing improve by 7% year-on-year. Emphasising this shift in perspectives, in 2021 there has been a five-fold increase  in Private Equity investments [totalling $1.5bn] into API companies across the country[2]. In fact, to help attendees explore this burgeoning sector further, the second day of CPhI & P-MEC India’s online conference will feature a live panel discussion on API & Next Gen Labs. The session will offer foresight into the emerging possibilities for automation and robotics in pharmaceutical manufacturing as well as evaluating the complexity of the global API supply chain (Tuesday 16th November– Online ).

In another boon to Indian manufacturing, the country showed the largest gains in terms of ‘growth potential for biologics manufacturing’ of any country – including traditional biologics powerhouses France, the USA, Singapore, and the UK – perhaps helped by the Serum Institute of India’s well documented supply of Covid vaccines. Highlighting this issue’s current prominence in India, a panel of experts, moderated by Duncan Emerton, executive director, custom intelligence & analytics at Informa Pharma Intelligence, will explore the opportunities and challenges for biologics and biosimilars. (Wednesday 17th November Online ).

To enhance networking and deal-making at the event, the online event platform will open more than a week before the start of the in-person event, empowering the industry to maximise the value they get from the in-person CPhI & P-MEC India. This enables companies to identify more partners in advance and pre-qualify their leads. The online platform will also play host to some 30 sessions spanning four tracks – Drug Development and Delivery, API & Next Gen Labs, Biosimilars & mAbs and Digitization. Running alongside the event is India Pharma week which will host the ‘Women in Pharma’ roundtable as well as the eighth annual India Pharma Awards.

Silvia Forroova, Brand Director at Informa, said it best: “It is such an exciting time with a multitude of new opportunities emerging out of India, which is why we are really looking forward to hosting the hybrid CPhI & P-MEC India. With so many opportunities to network over the course of the fortnight, I would encourage everyone to take advantage of the online platform to not only set-up virtual meetings, but to also pre-qualify leads ahead of the in-person event.”

Registration for CPhI & P-MEC India is now open and to get more information about the digital content programme, exhibitor and networking opportunities, please visit:


Notes to editors

About CPhI

CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, Korea, China, India, Japan, South East Asia, North America, and the Middle East and Africa. Co-locating with ICSE for contract services; P-MEC for machinery, equipment & technology; InnoPack for pharmaceutical packaging; bioLIVE for biopharma; and Finished Dosage Formulation for every aspect of the finished dosage supply chain.  CPhI provides an online buyer and supplier directory at

For more information visit

About Informa Markets

Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organizer, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year.

For more information, please visit

The Informa Markets annual schedule of Pharmaceutical eventsnclude: Korea (11-13 October 2021), COEX – Seoul, Korea); Pharmapack Europe 2021 (13-14 October, 2021 at the Paris Expo, Porte de Versailles – Paris, France); CPhI, ICSE, P-MEC, FDF, InnoPack Worldwide, BioProduction (09 November – 11 November 2021 at Fiera Milano, Milan);  CPhI & P-MEC India (24-26 November 2021 at the India Expo Mart, Greater Noida, Delhi NCR – Delhi, India); CPhI & P-MEC China (Dec. 16 to 18, 2021 at SNIEC – Shanghai, China); CPhI Japan (20-22 April, 2022 at the Big Sight Exhibition Centre – Tokyo, Japan);

For media enquiries, please contact:

Alex Heeley or Abdul Khalifeh

De Facto Communications

T: +44 (0) 203 735 8168

E: /


[1] The full survey findings and annual report will be released at CPhI Worldwide, however, an advanced copy is available to anyone that registers to attend



Subscribe to Newsletter
Share this:              


There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *